Upadacitinib Global Market Report 2025

Upadacitinib is a Janus kinase (JAK) inhibitor used to treat various inflammatory conditions by targeting and inhibiting specific enzymes involved in the inflammatory process. It is prescribed for moderate to severe rheumatoid arthritis (RA) and other autoimmune diseases, offering a targeted therapy alternative to traditional disease-modifying anti-rheumatic drugs (DMARDs) and biologics, with the added convenience of oral administration.

The primary product types of upadacitinib include Janus kinase inhibitors, antirheumatic agents, and small molecule drugs. Janus kinase (JAK) inhibitors work by blocking the activity of Janus kinase enzymes to reduce inflammation and manage autoimmune diseases. Upadacitinib is used for various applications, such as rheumatoid arthritis, psoriatic arthritis, and Crohn's disease, and is utilized by multiple end users, including hospitals, home care, specialty clinics, and others.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sharp rise in U.S. tariffs and the resulting trade tensions in spring 2025 are having a significant impact on the healthcare sector, especially in the supply of essential medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are grappling with higher costs for imported surgical tools, imaging systems, and consumables like syringes and catheters, many of which have limited domestic substitutes. These escalating expenses are putting pressure on healthcare budgets, prompting some providers to delay equipment upgrades or pass increased costs on to patients. Furthermore, tariffs on raw materials and components are disrupting the manufacturing of vital drugs and devices, leading to supply chain delays. In response, the industry is adopting diversified sourcing strategies, expanding local production where feasible, and pushing for tariff exemptions on critical medical products.

The upadacitinib market research report is one of a series of new reports from The Business Research Company that provides upadacitinib market statistics, including the upadacitinib industry global market size, regional shares, competitors with the upadacitinib market share, detailed upadacitinib market segments, market trends, and opportunities, and any further data you may need to thrive in the upadacitinib industry. This upadacitinib market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The upadacitinib market size has grown rapidly in recent years. It will grow from $1.32 billion in 2024 to $1.5 billion in 2025 at a compound annual growth rate (CAGR) of 13.8%. The growth in the historic period can be attributed to the rising incidence of autoimmune diseases, programs for patient assistance, the rise in positive regulatory approvals in different nations, the increase in disposable income, and the rise in healthcare infrastructure.

The upadacitinib market size is expected to see rapid growth in the next few years. It will grow to $2.54 billion in 2029 at a compound annual growth rate (CAGR) of 14.1%. The growth in the forecast period can be attributed to the rise in rheumatoid arthritis incidence, programs for patient assistance, the rise in acceptance of traditional DMARDs, government innovations to spread awareness of rheumatoid arthritis symptoms, and rising FDA approvals for the treatment. Major trends in the forecast period include adoption of targeted therapies and biomarkers, real-world data analysis, emphasis on value-based care, development of specific JAK inhibitors, and growing advancements in biologics.

The forecast of 14.1% growth over the next five years reflects a modest reduction of 0.4% from the previous estimate for this market. This reduction is primarily due to the impact of tariffs between the US and other countries. Tariff barriers are expected to hamper the U.S. by increasing the cost of upadacitinib (JAK inhibitor) sourced from Switzerland and Ireland, thereby delaying treatment for rheumatoid arthritis and ulcerative colitis and elevating specialty pharmacy expenditures. The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.

The increasing incidence of autoimmune diseases is expected to drive the growth of the upadacitinib market in the coming years. Autoimmune diseases occur when the immune system mistakenly attacks the body's healthy cells, misidentifying them as foreign threats. The rising occurrence of these diseases is attributed to genetic predisposition, environmental triggers, and shifts in lifestyle and immune system function. Upadacitinib plays a crucial role in managing autoimmune conditions by selectively inhibiting JAK1, thereby reducing inflammation and modulating immune responses in disorders such as rheumatoid arthritis and psoriatic arthritis. For instance, in November 2024, Versorgungsatlas de, a Germany-based healthcare data analytics company, reported that 6,304,340 individuals were diagnosed with at least one autoimmune disease in 2022, corresponding to a raw prevalence rate of 8.61%. As a result, the increasing prevalence of autoimmune diseases is fueling the expansion of the upadacitinib market.

Companies operating in the upadacitinib market are prioritizing the development of innovative treatments, such as oral Janus kinase (JAK) inhibitors, to enhance options for managing autoimmune diseases. These oral inhibitors are small-molecule drugs that block Janus kinase enzymes, suppressing excessive immune activity and inflammation to effectively treat autoimmune and inflammatory conditions. For example, in April 2023, AbbVie Inc., a US-based pharmaceutical company, announced that RINVOQ (upadacitinib) had received European Commission approval for the treatment of moderately to severely active Crohn's disease. This oral formulation enables once-daily administration, improving patient adherence and treatment convenience. Compared to traditional therapies, the oral delivery method provides a faster onset of action, making it easier for patients to maintain their treatment regimens.

In November 2022, Caplin Point Laboratories Limited, an India-based pharmaceutical company, acquired an API plant from Metrochem API Private Limited for an undisclosed amount. This acquisition strengthens Caplin Point Laboratories' capacity to manufacture a wider range of high-quality API products, reinforcing its supply chain and expanding its reach in regulated markets. Metrochem API Private Limited, also based in India, is a pharmaceutical company involved in the production of upadacitinib.

Major players in the upadacitinib market are Merck & Co. Inc., AbbVie Inc, Eli Lilly and Company, Curia Global Inc., Egis Pharmaceuticals PLC, Natco Pharma, Morepen Laboratories, Zhejiang Hengkang Pharmaceutical, Sinoway industrial Co. Ltd., Optimus Pharma, Venkatasai Life Sciences, Shandong Chenghui Shuangda Pharmaceutical Co. Ltd., Jinan Tantu Chemicals Co. Ltd., Shandong Loncom Pharmaceutical Co. Ltd., Lee Pharma, TAPI Technology & API Services, Hebi Xinhe Pharmaceutical, Suzhou PengXu PharmaTech Co. Ltd., Anhui Dexinjia Biopharm Co. Ltd., Sichuan Qingmu Pharmaceutical Co. Ltd., Shandong Boyuan Pharmaceutical.

North America was the largest region in the upadacitinib market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in upadacitinib report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the upadacitinib market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The upadacitinib market consists of sales of immunosuppressants and anti-inflammatory agents. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Upadacitinib Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on upadacitinib market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, post-pandemic supply chain realignment, inflation and interest rate fluctuations, and evolving regulatory landscapes.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for upadacitinib ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The upadacitinib market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Product: Janus Kinase Inhibitors; Antirheumatic Agents; Small Molecule Drugs
• 2) By Application: Rheumatoid Arthritis; Psoriatic Arthritis; Crohn's Disease
• 3) By End-User: Hospitals; Homecare; Specialty Clinics; Other End-Users
• Subsegments:
• 1) By Janus Kinase Inhibitors: JAK1 Inhibitors; JAK2 Inhibitors; JAK3 Inhibitors; TYK2 Inhibitors
• 2) By Antirheumatic Agents: Disease-Modifying Antirheumatic Drugs (DMARDs); Biologic DMARDs; Conventional Synthetic DMARDs
• 3) By Small Molecule Drugs: Oral Small Molecule Drugs; Topical Small Molecule Drugs
• Companies Mentioned: Merck & Co. Inc.; AbbVie Inc; Eli Lilly and Company; Curia Global Inc.; Egis Pharmaceuticals PLC; Natco Pharma; Morepen Laboratories; Zhejiang Hengkang Pharmaceutical; Sinoway industrial Co. Ltd.; Optimus Pharma; Venkatasai Life Sciences; Shandong Chenghui Shuangda Pharmaceutical Co. Ltd.; Jinan Tantu Chemicals Co. Ltd.; Shandong Loncom Pharmaceutical Co. Ltd.; Lee Pharma; TAPI Technology & API Services; Hebi Xinhe Pharmaceutical; Suzhou PengXu PharmaTech Co. Ltd.; Anhui Dexinjia Biopharm Co. Ltd.; Sichuan Qingmu Pharmaceutical Co. Ltd.; Shandong Boyuan Pharmaceutical
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain.
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time Series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: PDF, Word and Excel Data Dashboard.